Lori Hu

Lori Hu has been working in the venture capital and business development sectors since 2012. Lori began their career as an Associate Director of Business Development at Bristol-Myers Squibb in 2012. In 2014, they joined S.R. One Ltd as a VC Associate. In 2015, Hu became a Board Observer for both Moximed and Ivantis, Inc. Lori also began working as a Managing Director for Vertex Ventures HC, a venture fund network under Vertex Venture Holdings, anchored by Temasek Holdings. In 2018, Hu took on a Board Director role for Palleon Pharmaceuticals and BlackThorn Therapeutics. In 2019, they joined Elevation Oncology as a Board Director and in 2021, Neuspera Medical Inc. as a Board Director. Hu is currently a Board Director at Indapta Therapeutics.

Lori Hu has a Master of Business Administration (M.B.A.) from The Wharton School, a Master's Degree in International Studies from The Lauder Institute - University of Pennsylvania, and a Bachelor of Science in Biomedical Engineering from Duke University.